David A Rosa bought $50k of NMTC
CEO and President at NEUROONE MEDICAL TECHNOLOGIES Corp. 100,000 shares at an average of $0.50, traded Apr 4, 2025, filed Apr 7, 2025.
Score components
- +25RoleCEO
- +7Trade size$50k at market
- +3Relative to holdingsHoldings up 9%
- +18Price context0% above the 52-week low; 61% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +50.8%, 3m +68.8%, 6m +130.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001540354-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 4, 2025 | POpen-market purchase Common Stock | +100,000 | $0.50 | $50k | 1,161,289 | Apr 7, 2025 |
Related signals
Other insiders at NEUROONE MEDICAL TECHNOLOGIES Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | NMTCbuy NEUROONE MEDICAL TECHNOLOGIES Corp | David J. Wambeke Chief Business Officer | $67k 33,333 shares | +20% | |
| 15Weak | NMTCsell NEUROONE MEDICAL TECHNOLOGIES Corp | Mark Christianson Business Development Director | $11k 15,363 shares | -7% | |
| 15Weak | NMTCsell NEUROONE MEDICAL TECHNOLOGIES Corp | Mark Christianson Business Development Director | $734 917 shares | -0% | |
| 15Weak | NMTCsell NEUROONE MEDICAL TECHNOLOGIES Corp | Mark Christianson Business Development Director | $11k 13,720 shares | -6% | |
| 51Moderate | NMTCbuy NEUROONE MEDICAL TECHNOLOGIES Corp | David J. Wambeke Chief Business Officer | $670k 1,000,000 shares | - | |
| 20Weak | NMTCsell NEUROONE MEDICAL TECHNOLOGIES Corp | Mark Christianson Business Development Director | $22k 30,000 shares | -11% | |
| 15Weak | NMTCsell NEUROONE MEDICAL TECHNOLOGIES Corp | Mark Christianson Business Development Director | $5,804 10,000 shares | -4% | |
| 15Weak | NMTCsell NEUROONE MEDICAL TECHNOLOGIES Corp | Mark Christianson Business Development Director | $5,596 8,981 shares | -3% | |
| 15Weak | NMTCsell NEUROONE MEDICAL TECHNOLOGIES Corp | Mark Christianson Business Development Director | $7,306 11,019 shares | -4% | |
| 68Notable | NEUROONE MEDICAL TECHNOLOGIES Corp | Ronald W. McClurg Chief Financial Officer | $100k 200,000 shares | +82% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.